Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 3;5(2):11.
doi: 10.3390/epigenomes5020011.

Firing up Cold Tumors-Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy

Guan-Ling Lin  1   2 , Leah H J Tsai  1   2 , Peter J K Kuppen  3 , Michael W Y Chan  1   2
Affiliations
Editorial

Firing up Cold Tumors-Targeting the Epigenetic Machinery to Enhance Cancer Immunotherapy

Guan-Ling Lin et al. Epigenomes. .

Abstract

Cancer immunotherapy using monoclonal antibodies targeting immune checkpoint proteins, such as PD-L1 or PD-1 (i [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Tumors may escape immunosurveillance by epigenetic silenicng of immune-related genes (for example, Th1-type chemokine), leading to a non-inflammed “cold” tumor. Treatment with epigenetic inhibitors (epi-drugs) restores the expression of those immune-related genes, resulting in the infiltration of immunocytes (i.e., hot tumor) and restoring the sensitivity of the tumor cells to immune checkpoint blockade.
See this image and copyright information in PMC

References

    1. Powles T., Park S.H., Voog E., Caserta C., Valderrama B.P., Gurney H., Kalofonos H., Radulović S., Demey W., Ullén A., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 2020;383:1218–1230. doi: 10.1056/NEJMoa2002788. - DOI - PubMed
    1. Li J., Wang W., Zhang Y., Cieślik M., Guo J., Tan M., Green M.D., Wang W., Lin H., Li W., et al. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. J. Clin. Investig. 2020;130:2712–2726. doi: 10.1172/JCI134402. - DOI - PMC - PubMed
    1. Nagarsheth N., Peng D., Kryczek I., Wu K., Li W., Zhao E., Zhao L., Wei S., Frankel T.L., Vatan L., et al. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res. 2016;76:275–282. doi: 10.1158/0008-5472.CAN-15-1938. - DOI - PMC - PubMed
    1. Peng D., Kryczek I., Nagarsheth N., Zhao L., Wei S., Wang W., Sun Y., Zhao E., Vatan L., Szeliga W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nat. Cell Biol. 2015;527:249–253. doi: 10.1038/nature15520. - DOI - PMC - PubMed
    1. Lee Y.-T., Chuang Y.-M., Chan M.W.Y. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes. 2020;4:27. doi: 10.3390/epigenomes4040027. - DOI - PMC - PubMed

Publication types